Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit

High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules

MTH-68/H oncolytic viral treatment in human high-grade gliomas

Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus

Overview of phase I studies of intravenous administration of PV701, an oncolytic virus

Recombinant Newcastle disease virus as a vaccine vector

TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus

Postirradiation malignant fibrous histiocytoma of the larynx: a case report